Search website

If you cannot find, what you are looking for, try searching for it below or visit our FAQ-page.

Close
News & Events »
Innovation: Poster on OPTICORE<sup>TM</sup> Nominated for the 2018 AAPS Best Abstract Award

Press Release

Innovation: Poster on OPTICORETM Nominated for the 2018 AAPS Best Abstract Award

RHEINFELDEN, Switzerland, 22 October 2018 – Tillotts Pharma AG (“Tillotts”) is proud[...] Read more »
Tillotts Pharma AG and Zeria Group appoint Dr. Karima Boubekeur as new Global Head of Innovation

Press Release

Tillotts Pharma AG and Zeria Group appoint Dr. Karima Boubekeur as new Global Head of Innovation

RHEINFELDEN, Switzerland, September 3rd 2018 – Tillotts Pharma AG (“Tillotts”) an[...] Read more »
Tillotts Pharma AG signs POTELLIGENT<sup>®</sup> CHOK1SV<sup>TM</sup> Cell Line Technology Licensing Agreement with Lonza and BioWa

Press Release

Tillotts Pharma AG signs POTELLIGENT® CHOK1SVTM Cell Line Technology Licensing Agreement with Lonza and BioWa

• Tillotts Pharma AG will use the POTELLIGENT® CHOK1SV™ Cell Line, developed by Lonza[...] Read more »
Tillotts Pharma AG opens new, state-of-the-art office in Rheinfelden, Switzerland

Press Release

Tillotts Pharma AG opens new, state-of-the-art office in Rheinfelden, Switzerland

PRESS RELEASE RHEINFELDEN, Switzerland, March 5th, 2018 Tillotts Pharma AG (Tillotts[...] Read more »
Tillotts Pharma announces MHRA<sup>1</sup> approval of Entocort<sup>TM</sup> Capsules for Microscopic Colitis

Press Release

Tillotts Pharma announces MHRA1 approval of EntocortTM Capsules for Microscopic Colitis

PRESS RELEASE RHEINFELDEN, Switzerland, February 5th 2018 – Tillotts Pharma AG (“T[...] Read more »
Tillotts Pharma AG signs license agreement on antibody technology with Inven2

Press Release

Tillotts Pharma AG signs license agreement on antibody technology with Inven2

RHEINFELDEN, Switzerland, January 22, 2018 Inven2 AS (Inven2), a technology transfer an[...] Read more »
1 2 3 4 6